Overview
To Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
Status:
Active, not recruiting
Active, not recruiting
Trial end date:
2023-08-01
2023-08-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To demonstrate that CT-P16 is similar to US-approved Avastin in terms of efficacy determined by overall response rate (ORR) up to Cycle 6 during the Induction Study PeriodPhase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
CelltrionTreatments:
Bevacizumab
Criteria
Inclusion Criteria:- diagnosed as recurrent disease or stage IV
- has at least 1 measurable lesion by Response Evaluation Criteria in Solid Tumor
(RECIST) Version 1.1
Exclusion Criteria:
- has predominantly squamous cell histology non-small cell lung cancer
- had surgery for metastatic nsNSCLC